BR0207272A - Método de tratamento de doenças ou condições de desmielinação - Google Patents

Método de tratamento de doenças ou condições de desmielinação

Info

Publication number
BR0207272A
BR0207272A BR0207272-6A BR0207272A BR0207272A BR 0207272 A BR0207272 A BR 0207272A BR 0207272 A BR0207272 A BR 0207272A BR 0207272 A BR0207272 A BR 0207272A
Authority
BR
Brazil
Prior art keywords
conditions
compounds
useful
treatment
treating disease
Prior art date
Application number
BR0207272-6A
Other languages
English (en)
Inventor
Craig P Smith
Michael P Rathbone
Margaret Petty
David Rampe
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of BR0207272A publication Critical patent/BR0207272A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

"MéTODO DE TRATAMENTO DE DOENçAS OU CONDIçõES DE DESMIELINAçãO". N-(Piridinil)-1 H-indol-1 -aminas da fórmula I provêem uma combinação única de propriedades de bloqueio para ambos canais de potássio e sódio. Esses compostos são úteis para o tratamento de Doenças e Condições de Desmielinação tal como Esclerose Múltipla, Dano ao Cordão Espinhal, Dano Cerebral Traumático e Acidente vascular cerebral. Os compostos são também úteis para Reabilitação de Acidente vascular cerebral, para tratamento de Irritação e Disfunção da Bexiga e para o tratamento de Dor Neuropática e Dor lnduzida por quimiocina.
BR0207272-6A 2001-02-15 2002-02-14 Método de tratamento de doenças ou condições de desmielinação BR0207272A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26884601P 2001-02-15 2001-02-15
GBGB0119435.6A GB0119435D0 (en) 2001-02-15 2001-08-09 Method of treating of demyelinating diseases or conditions
PCT/US2002/005501 WO2002064126A2 (en) 2001-02-15 2002-02-14 Method of treating of demyelinating diseases or conditions

Publications (1)

Publication Number Publication Date
BR0207272A true BR0207272A (pt) 2004-02-10

Family

ID=23024747

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0207272-6A BR0207272A (pt) 2001-02-15 2002-02-14 Método de tratamento de doenças ou condições de desmielinação

Country Status (39)

Country Link
US (10) US6967210B2 (pt)
EP (1) EP1368031A2 (pt)
JP (3) JP2004518711A (pt)
KR (3) KR100951540B1 (pt)
CN (2) CN100522164C (pt)
AP (1) AP1749A (pt)
AR (1) AR035750A1 (pt)
AU (3) AU2002247200B9 (pt)
BR (1) BR0207272A (pt)
CA (1) CA2438712A1 (pt)
CO (1) CO5390085A1 (pt)
CR (1) CR7023A (pt)
CZ (1) CZ20032172A3 (pt)
EA (2) EA012409B1 (pt)
EC (1) ECSP024218A (pt)
EE (1) EE200300363A (pt)
GB (1) GB0119435D0 (pt)
HK (1) HK1080361B (pt)
HR (1) HRP20030652A2 (pt)
HU (1) HUP0303203A3 (pt)
IL (2) IL157341A0 (pt)
MA (1) MA26152A1 (pt)
ME (1) MEP21208A (pt)
MX (1) MXPA03006110A (pt)
MY (1) MY157745A (pt)
NO (1) NO20033622L (pt)
NZ (4) NZ544720A (pt)
OA (1) OA12549A (pt)
PA (1) PA8540101A1 (pt)
PE (1) PE20040175A1 (pt)
PL (1) PL363638A1 (pt)
SG (1) SG134170A1 (pt)
SK (1) SK10392003A3 (pt)
TR (4) TR200301330T2 (pt)
TW (1) TWI325319B (pt)
UA (2) UA80394C2 (pt)
WO (1) WO2002064126A2 (pt)
YU (1) YU62903A (pt)
ZA (1) ZA200306124B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0119435D0 (en) * 2001-02-15 2001-10-03 Aventis Pharm Prod Inc Method of treating of demyelinating diseases or conditions
BR0317606A (pt) * 2002-12-20 2005-11-29 Dynogen Pharmaceuticals Inc Métodos de tratamento de distúrbios não dolorosos da bexiga urinária que usam moduladores de canal de cálcio de subunidade (alfa)2(delta)
AU2004207010A1 (en) * 2003-01-30 2004-08-12 Dynogen Pharmaceuticals, Inc. Methods of treating lower urinary tract disorders using sodium channel modulators
US20040198822A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmacueticals, Inc. Methods for treating lower urinary tract disorders using alpha2delta subunit calcium channel modulators with smooth muscle modulators
GT200500063A (es) * 2004-04-01 2005-10-14 Metodo para tratar la esquizofrenia y/o anormalidades glucoregulatorias
GB0510164D0 (en) * 2005-04-28 2005-06-22 Paradigm Therapeutics Ltd Ion channel
FR2892022B1 (fr) * 2005-10-19 2008-01-04 Urogene Sa Traitement des symptomes de l'irritation de la vessie
FR2892021B1 (fr) * 2005-10-19 2008-01-04 Urogene Traitement de l'incontinence urinaire d'effort et mixte
US8420593B1 (en) * 2006-06-16 2013-04-16 Landon C. G. Miller Compositions and methods for regulating membrane potential
DE102008044844B4 (de) * 2008-08-28 2018-08-30 Siemens Healthcare Gmbh Verfahren zur Ermittlung einer Schwächungskarte zur Verwendung in der Positronenemissionstomographie und von Homogenitätsinformationen des Magnetresonanzmagnetfeldes
KR101862539B1 (ko) * 2010-03-26 2018-05-31 가부시키가이샤 한도오따이 에네루기 켄큐쇼 반도체 장치
US20130184316A1 (en) * 2010-07-15 2013-07-18 Andrew Hornstein Methods for diagnosing and treating concussive disorders
EP2995305B1 (en) * 2011-01-28 2020-03-04 Acorda Therapeutics, Inc. Use of potassium channel blockers to treat cerebral palsy
TWI592156B (zh) * 2011-10-04 2017-07-21 艾可達醫療公司 使用胺基吡啶以治療與中風有關之感覺動作損傷之方法
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
EP3727587A4 (en) 2017-12-22 2022-02-23 Massachusetts Institute Of Technology COMPOSITIONS AND METHODS FOR THERAPY OF WILLIAMS SYNDROME (WS)
CN116723870A (zh) * 2021-01-20 2023-09-08 拉什大学医学中心 球形细胞脑白质营养不良症或克拉伯病的改良治疗

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880822A (en) * 1987-04-24 1989-11-14 Hoechst-Roussel Pharmaceuticals, Inc. N-(pyridinyl)-1H-indol-1-amines
US4970218A (en) * 1987-04-24 1990-11-13 Hoechst-Roussel Pharmaceuticals Inc. N-(pyridinyl)-1H-indol-1-amines
ATE115143T1 (de) * 1987-04-24 1994-12-15 Hoechst Roussel Pharma N-(pyridinyl)-1h-indol-1-amine, verfahren zu deren herstellung und ihre verwendung als arzneimittel.
IL95251A (en) * 1989-08-02 1996-08-04 Hoechst Roussel Pharma 2,3-Dihydro-1- (pyridinylamino) - indoles, a method for their preparation and use as drugs
US5214038A (en) * 1991-04-15 1993-05-25 Hoechst-Roussel Pharmaceuticals Inc. 1-(pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1H-indoles and intermediates for the preparation thereof
DE4325491A1 (de) * 1993-07-29 1995-02-02 Boehringer Ingelheim Kg Verwendung von zentral wirksamen alpha-2-Agonisten zur Hemmung des Postaggressionsstoffwechsels
US5459274A (en) * 1994-05-13 1995-10-17 Hoechst-Roussel Pharmaceuticals Inc. Preparation of N-alkyl-N-pyridinyl-1H-indol-1-amines
US5565475A (en) * 1994-11-08 1996-10-15 Muhlhauser; Mark A. Method of treating urinary bladder dysfunctions with 3-tetrahydropyridine derivatives
EP0731108A1 (en) * 1995-03-10 1996-09-11 Boehringer Mannheim Gmbh Method of manufacturing a therapeutic agent for the regeneration of oligodendrocytes
FR2754147B1 (fr) 1996-10-03 2000-02-04 Mbh Technologies Sa Installation et procede pour le traitement de carcasses
DK1056754T3 (da) * 1998-01-29 2004-02-16 Bristol Myers Squibb Co Phosphatderivater af diaryl-1,3,4-oxadiazolon
WO2001004091A1 (en) * 1999-07-09 2001-01-18 Ortho-Mcneil Pharmaceutical, Inc. Neurotrophic 2-azetidinecarboxylic acid derivatives, and related compositions and methods
GB0119435D0 (en) * 2001-02-15 2001-10-03 Aventis Pharm Prod Inc Method of treating of demyelinating diseases or conditions

Also Published As

Publication number Publication date
HRP20030652A2 (en) 2005-06-30
JP2010120958A (ja) 2010-06-03
US20050234105A1 (en) 2005-10-20
NZ544720A (en) 2007-08-31
SG134170A1 (en) 2007-08-29
CO5390085A1 (es) 2004-04-30
HUP0303203A3 (en) 2007-11-28
US7230015B2 (en) 2007-06-12
EA012409B1 (ru) 2009-10-30
US20050159456A1 (en) 2005-07-21
WO2002064126A3 (en) 2003-02-20
US7534803B2 (en) 2009-05-19
US6967210B2 (en) 2005-11-22
JP2009185045A (ja) 2009-08-20
CR7023A (es) 2003-11-17
US20090209594A1 (en) 2009-08-20
AU2002247200B2 (en) 2007-12-13
PL363638A1 (en) 2004-11-29
TR200800693T2 (tr) 2008-07-21
IL157341A (en) 2010-11-30
AU2008201179A1 (en) 2008-04-03
OA12549A (en) 2006-06-05
US20090270458A1 (en) 2009-10-29
AP2003002834A0 (en) 2003-09-30
US20030105150A1 (en) 2003-06-05
CN100522164C (zh) 2009-08-05
UA80394C2 (en) 2007-09-25
NO20033622D0 (no) 2003-08-14
AU2009238332A1 (en) 2009-12-10
ZA200306124B (en) 2004-11-08
HUP0303203A2 (hu) 2003-12-29
MXPA03006110A (es) 2005-07-01
CZ20032172A3 (cs) 2004-01-14
PE20040175A1 (es) 2004-03-29
SK10392003A3 (sk) 2004-01-08
TWI325319B (en) 2010-06-01
CN1529598A (zh) 2004-09-15
EP1368031A2 (en) 2003-12-10
IL157341A0 (en) 2004-02-19
HK1080361A1 (en) 2006-04-28
KR20090005255A (ko) 2009-01-12
HK1080361B (zh) 2009-10-30
NO20033622L (no) 2003-10-06
US20090209595A1 (en) 2009-08-20
US20090281147A1 (en) 2009-11-12
US20040157888A1 (en) 2004-08-12
AU2002247200B9 (en) 2008-07-10
ECSP024218A (es) 2003-09-24
US20040157889A1 (en) 2004-08-12
EA200300882A1 (ru) 2003-12-25
CN1679564A (zh) 2005-10-12
KR20090005254A (ko) 2009-01-12
TR200800691T2 (tr) 2008-03-21
KR100951540B1 (ko) 2010-04-09
NZ556697A (en) 2009-01-31
TR200301330T2 (tr) 2004-12-21
MA26152A1 (fr) 2004-07-01
KR100951542B1 (ko) 2010-04-09
AU2008201179B2 (en) 2009-08-20
MY157745A (en) 2016-07-15
TR200800692T2 (tr) 2008-03-21
WO2002064126A2 (en) 2002-08-22
EA011319B1 (ru) 2009-02-27
EE200300363A (et) 2003-10-15
US20060025452A1 (en) 2006-02-02
JP2004518711A (ja) 2004-06-24
GB0119435D0 (en) 2001-10-03
PA8540101A1 (es) 2003-09-05
AR035750A1 (es) 2004-07-07
UA88773C2 (ru) 2009-11-25
EA200600896A1 (ru) 2006-08-25
US7179821B2 (en) 2007-02-20
MEP21208A (en) 2010-06-10
NZ527011A (en) 2005-07-29
NZ539159A (en) 2006-11-30
KR20040014459A (ko) 2004-02-14
YU62903A (sh) 2006-05-25
CA2438712A1 (en) 2002-08-22
AP1749A (en) 2007-06-13

Similar Documents

Publication Publication Date Title
BR0207272A (pt) Método de tratamento de doenças ou condições de desmielinação
DK1137762T3 (da) Behandling af Pompes sygdom
GB0225475D0 (en) Therapeutic agents
BR0116370A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
DE60316779D1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
WO2003032994A3 (de) 5-substituierte 4-amino-2-phenylamino-pyrimidinderivate und ihre verwendung als beta-amyloid modulatoren
GB0108592D0 (en) Therapeutic agents
BR0012450A (pt) Benzimidazóis substituìdos
GB0128108D0 (en) Therapeutic use
EA200200306A1 (ru) Трициклические ингибиторы поли(адф-рибозо)полимераз
ATE339187T1 (de) Verwendung von zusammensetzungen mit antiseptika und/oder die wundheilung fördernden wirkstoffen für den tieferen atemwegstrakt
UA27911C2 (uk) Засіб для лікування або запобігання фізіологічних розладів, які викликані надлишком тахікініну
UY26130A1 (es) Compuestos para tratar la obesidad
CY1105507T1 (el) Υποκατεστημενες πυραζολο- και θειαζολοπυριμιδινες
DE60318839D1 (de) 2,6-chinolinyl- und 2,6-naphthylderivate und deren verwendungen zur behandlung von vla-4 bezogenen krankheiten
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
BR0117009A (pt) Composiçoes para utilização no tratamento de distúrbios associados a ige
PT1562954E (pt) Antagonistas de ccr1 para o tratamento da doenca desmielinzante inflamatoria i.a.
DE69521536D1 (de) Zusammensetzungen die G-CSF und ein TNF-Bindungsprotein enthalten
BR0210401A (pt) Composto, composição farmacêutica, uso de um composto e método para o tratamento de um distúrbio ou de uma doença de um corpo de animal vivo, incluindo um humano
AU2003303217A8 (en) Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
EP1682518A4 (en) DIKATIONAL TRIARYLANALOGA AS MEANS AGAINST PROTOZOEN
IT1320192B1 (it) Composizione terapeutica per la cura della psoriasi.
BR0210407A (pt) Composto, composição farmacêutica, uso de um composto e método de tratamento de um distúrbio ou de uma doença de corpo animal vivo, incluindo um humano
ES2140544T3 (es) Utilizacion de efaroxan y de sus derivados para la fabricacion de medicamentos destinados al tratamiento de las enfermedades neurodegenerativas.

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: AVENTIS PHARMACEUTICALS, INC. (US)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020070165509/RJ DE 23/11/2007.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA INT.CL: A61K 31/4439, A61P 13/00, A61P 13/10, A61P 17/02, A61P 19/02, A61P 25/00, A61P 25/02,A61P 25/28, A61P 27/02, A61P 29/00, A61P 3/00, A61P 35/00, A61P 9/00, C07D 401/12

Ipc: A61K 31/00 (2011.01)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2156 DE 02/05/2012.